Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
This page provides a historical news archive for Accolade, Inc. (formerly Nasdaq: ACCD), a Personalized Healthcare company that combined virtual primary care and mental health, expert medical opinion, and care navigation for employers, health plans, and consumers. The news flow around Accolade documents its evolution as a public company and its eventual merger with Transcarent.
Readers can find company-issued announcements describing Accolade’s financial results, investor conference presentations, and guidance updates during its time as a listed company. These items include earnings releases, notices about upcoming quarterly results, and participation in healthcare and investor conferences, all framed around its Personalized Healthcare platform and focus on predictive engagement, proactive care, and addressing barriers to access and continuity of care.
The archive also includes press releases detailing strategic developments, such as the expansion of PlushCare, Accolade’s virtual health business unit, to accept Medicare Part B for direct-to-consumer virtual care. These releases describe efforts to broaden access to primary care, clinical weight management services, and mental health support for Medicare beneficiaries across all 50 states.
A significant portion of the news coverage centers on the acquisition of Accolade by Transcarent. Initial announcements describe a definitive agreement for Transcarent to acquire Accolade for cash consideration per share, followed by stockholder approval of the merger and, later, confirmation that the transaction was completed. These items explain that, after the merger, Accolade became part of a privately held company and its common stock would no longer be listed on Nasdaq or any public market.
Investors and researchers can use this news page to trace how Accolade positioned its Personalized Healthcare offerings, how it communicated with the market, and how the combination with Transcarent was described by both organizations over time.
Accolade (NASDAQ: ACCD) announced financial results for fiscal Q2 2025 ended August 31, 2024. Revenue increased 10% to $106.4 million, while net loss improved 27% to $23.9 million. Non-GAAP Adjusted EBITDA loss narrowed 68% to $2.8 million, and Adjusted Gross Margin expanded to 47.3%.
CEO Rajeev Singh stated that Accolade is positioned to deliver its first full year of Adjusted EBITDA profitability and positive cash flow. The company focuses on solving the Physician Gap through a physician-led advocacy approach. CFO Steve Barnes highlighted Accolade's execution in delivering profitable growth, with the net cash position improving by over $20 million compared to convertible debt in the past year.
Accolade, Inc. (NASDAQ: ACCD) has announced the release date for its fiscal second quarter 2025 financial results. The company will disclose the results on Tuesday, October 8, 2024, before market open. Following the release, Accolade will host a conference call at 8:00 a.m. E.T. to review the results.
Interested parties can participate in the conference call via telephone by pre-registering through a provided link. Upon registration, participants will receive dial-in information and a unique PIN. Alternatively, a live audio webcast of the call will be accessible online at the company's investor relations website. For those unable to attend live, a replay of the call will be available for one year via webcast on the same website.
Accolade (NASDAQ: ACCD) has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for Thursday, September 5 at 9:15 am ET in New York. Investors and interested parties can access a live webcast of the presentation through Accolade's investor relations website at ir.accolade.com. For those unable to attend or watch live, a replay of the presentation will be available on the same platform for 90 days following the event. This conference provides Accolade with an opportunity to showcase its healthcare technology solutions to a global audience of investors and industry professionals.
Celeste Health Solutions, a new healthcare company, is entering the market with an innovative approach to simplify healthcare access for employees and ease the burden for employers. The company integrates health navigation, personalized engagement, whole-person virtual care, point solutions, care management, and benefits support into a single, comprehensive product.
Key features of Celeste include:
- Smart care plans for each plan member
- An intuitive app for accessing all benefits
- Direct communication with Care Advocates
- The Innovations Hub, a curated portfolio of point solutions
- Consolidated contracting, billing, and reporting for employers
Celeste is partnering with Accolade (ACCD) to enhance personalization of health management services, combining virtual care options, expert medical opinions, clinical integration, and seamless navigation.
Accolade (NASDAQ: ACCD) has announced its participation in the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase in Boston. The presentation is scheduled for Wednesday, August 14 at 12:00 pm ET. Investors and interested parties can access a live webcast of the presentation through the company's investor relations website at ir.accolade.com. For those unable to attend or watch live, a replay of the presentation will be available on the same website for 90 days following the event.
This conference provides Accolade with an opportunity to showcase its growth strategies and recent developments to a wide audience of investors and industry professionals. The company's participation in such a prominent event suggests confidence in its business model and future prospects.
Accolade (NASDAQ: ACCD) announced its fiscal first-quarter 2025 results, highlighting significant improvements. The company reported a revenue increase of 18% year-over-year, reaching $110.5 million. Net loss improved by 28%, down to $27.6 million from $38.4 million in the same period last year. Adjusted EBITDA saw a substantial improvement of 73%, landing at negative $3.3 million compared to negative $12.6 million. Adjusted gross profit also rose by 30%, totaling $52.8 million, with an adjusted gross margin of 47.8%, up from 43.5%.
CEO Rajeev Singh emphasized Accolade's continued focus on healthcare accessibility and outcomes through their physician-led advocacy approach. CFO Steve Barnes highlighted the company's commitment to achieving profitable growth and positive Adjusted EBITDA within the year.
Accolade (NASDAQ: ACCD) announced the release date for its fiscal first quarter 2025 financial results. The report will be available on June 27, 2024, after the market closes. A conference call to review these results is scheduled for the same day at 4:30 p.m. ET. Interested parties must pre-register for the call, which will be accessible via telephone and a live audio webcast on Accolade's investor relations website. A replay of the call will be available for one year.
Accolade (NASDAQ: ACCD) has announced its participation in the William Blair Growth Stock Conference in Chicago. The company will present on June 4, 2024, at 2:00 pm CT. A webcast and a 90-day replay will be available on their investor relations website.
Accolade (Nasdaq: ACCD) has announced a partnership with Noom to enhance its Trusted Partner Ecosystem. This collaboration offers a comprehensive solution for weight loss and metabolic health, integrating Noom's coaching with Accolade's primary care physicians. Noom Med, part of this partnership, focuses on obesity management, including GLP-1 medications and other anti-obesity drugs. Noom's approach combines psychology, science, and personalized support, achieving a 25% employee adoption rate and 42% of users maintaining weight loss for two years. This partnership aims to reduce obesity-related healthcare costs and improve outcomes through evidence-based care and advanced primary care support.
Summary not available.
FAQ
What is the current stock price of Accolade (ACCD)?
What is the market cap of Accolade (ACCD)?
